32 research outputs found
Characteristics of HIV-infected patients coinfected by HCV genotype 1 treated with pegylated interferon alpha 2a plus ribavirin (n = 187), grouped as a function of the presence or absence of rapid virological response.
<p>Abbreviations: SNP: Single nucleotide polymorphism. RVR: Rapid virologic response. ETR: Virologic response at the end of treatment. SVR: Sustained virologic response.</p
Percentages of HIV/HCV coinfected patients (HCV genotype 1) with rapid (lined) and sustained (black) virological response to pegylated interferon-α 2a plus ribavirin as a function of IL28B polymorphism and HCV-RNA levels.
<p>Percentages of HIV/HCV coinfected patients (HCV genotype 1) with rapid (lined) and sustained (black) virological response to pegylated interferon-α 2a plus ribavirin as a function of IL28B polymorphism and HCV-RNA levels.</p
Characteristics of HIV-HCV coinfected patients treated with pegylated interferon-α 2a plus ribavirin (n = 267), grouped as a function of HCV genotype and presence or absence of sustained virological response.
<p>Abbreviations: SNP: Single nucleotide polymorphism. RVR: Rapid virologic response. ETR: Virologic response at the end of treatment. SVR: Sustained virologic response.</p
Response to pegylated interferon-α 2a plus ribavirin of 267 HIV/HCV coinfected patients, grouped as a function of HCV genotype.
<p>Data are shown as absolute number (percentage).</p
Characteristics of HIV-HCV coinfected patients treated with pegylated interferon alpha 2a plus ribavirin (n = 267), distributed as a function of the presence or absence of significant liver fibrosis (F3 or F4).
<p>Abbreviations: SNP: Single nucleotide polymorphism. RVR: Rapid virologic response. ETR: Virologic response at the end of treatment. SVR: Sustained virologic response.</p
Percentages of HIV/HCV coinfected patients with sustained virological response to pegylated interferon-α 2a plus ribavirin as a function of IL28B polymorphism, HCV-RNA levels and presence (black) or absence (white) of significant liver fibrosis.
<p>Percentages of HIV/HCV coinfected patients with sustained virological response to pegylated interferon-α 2a plus ribavirin as a function of IL28B polymorphism, HCV-RNA levels and presence (black) or absence (white) of significant liver fibrosis.</p
Adverse events or intercurrent illness throughout treatment with weekly pegIFN-α-2a (135 µg) plus oral Ribavirin (400 mg twice daily); n = 58 patients.
<p>Adverse events or intercurrent illness throughout treatment with weekly pegIFN-α-2a (135 µg) plus oral Ribavirin (400 mg twice daily); n = 58 patients.</p
Factors predictive of rapid (RVR) and sustained virological response (SVR) to anti-hepatitis C virus therapy.
<p>TDF: tenofovir. ABV: abacavir. n.a.: not applicable.</p
Viral responses in HCV/HIV-coinfected patients treated with pegIFN α-2a (135 µg/week) plus ribavirin (800 mg/day).
<p>ITT: intention to treat. RVR: rapid virological response. EVR: early virological response. ETR: end of treatment response. SVR: sustained virological response.</p
Percentage of virological responses and relapses as function of rs129679860 genotype (CC vs. CT/TT).
<p>RVR: rapid virological response; EVR: early virological response; ETR: end of treatment response; SVR: sustained virological response.</p